Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. reports developments tied to its commercial eye-care franchise and biopharmaceutical pipeline. Company news commonly covers XDEMVY, its lotilaner ophthalmic solution marketed in the U.S. for Demodex blepharitis, including product-sales updates, prescribing trends, conference presentations, and international regulatory milestones for TP-03 through its Greater China partner.
Updates also address pipeline programs such as TP-04 for ocular rosacea and TP-05, an investigational oral lotilaner tablet being studied for Lyme disease prevention. Recurring corporate items include quarterly and annual financial results, investor-conference participation, board and governance changes, and business updates related to Tarsus' ophthalmology-focused commercialization strategy.
Tarsus Pharmaceuticals (NASDAQ: TARS) reported substantial advancements in its pipeline, particularly for TP-03, targeting Demodex blepharitis, with pivotal Saturn-2 trial data expected in April 2022 and NDA submission planned within the year. The company completed enrollment in this trial, following successful results from the Saturn-1 trial. Tarsus holds $171.8 million in cash as of December 31, 2021, ensuring a cash runway into the second half of 2024. The firm also advanced TP-05 for Lyme disease and secured a $175 million non-dilutive credit facility, enhancing financial flexibility and growth potential.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced its participation in two major healthcare conferences on March 16, 2022. The company will engage in a virtual fireside chat at the Oppenheimer’s 32nd Annual Healthcare Conference at 9:40am PT and a corporate presentation at the Barclays Global Healthcare Conference at 1:50pm PT. Tarsus focuses on innovative treatments in eye care and other therapeutic categories, with investigational products in clinical trials addressing significant unmet needs. Live webcasts will be available on their website.
Tarsus Pharmaceuticals has appointed Dr. José Trevejo as Chief Medical Officer, bringing over 20 years of clinical development experience. This strategic move aims to advance TP-03, Tarsus' investigational treatment for Demodex blepharitis, with an NDA submission anticipated later this year. Dr. Trevejo's expertise in drug development and infectious diseases is expected to enhance Tarsus' pipeline across various therapeutic areas. The company is currently conducting its second pivotal trial for TP-03, while also developing TP-05 for Lyme disease prevention.
Tarsus Pharmaceuticals (NASDAQ: TARS) is hosting a live webcast on February 8, 2022, at 9 a.m. PT, focusing on Demodex blepharitis and its investigational treatment TP-03. Expert speakers include CEO Bobak Azamian and leading ophthalmologists Eric Donnenfeld, Paul Karpecki, and Elizabeth Yeu. The agenda includes insights into the prevalence of Demodex blepharitis, clinical data for TP-03, and a Q&A session. TP-03, an anti-parasitic solution, has shown promise in clinical trials and targets a significant unmet need in eye care.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced the completion of enrollment for its pivotal Phase 3 trial, Saturn-2, evaluating TP-03 for Demodex blepharitis, with 408 patients participating. Topline results are expected in April 2022, with plans for a New Drug Application (NDA) submission if results are favorable. Additionally, Tarsus secured a $175 million non-dilutive credit facility from Hercules Capital and Silicon Valley Bank, enhancing its financial flexibility. This funding supports the advancement of TP-03 and the company's business growth.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced the appointment of Dr. Elizabeth Yeu to its Board of Directors while she continues as Chief Medical Advisor. Dr. Yeu brings over 20 years of eye care expertise, enhancing the company's leadership during a crucial phase as it prepares for the potential commercialization of TP-03, aimed at treating Demodex blepharitis. Her extensive background as an ophthalmologist and involvement in various medical boards positions Tarsus for strategic growth and innovation in its pipeline.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has announced its participation in two upcoming virtual investor conferences to discuss advancements in eye care and other therapeutic categories. The events are Ophthalmology Day at BTIG on November 30, 2021, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1-2, 2021. Tarsus is developing innovative treatments, including TP-03 for Demodex blepharitis in a Phase 3 trial and TP-05 for Lyme disease prevention in a Phase 1 trial. For updates, visit tarsusrx.com.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced that CEO Bobak Azamian will speak at the Virtual Jefferies London Healthcare Conference. The fireside chat will be available on-demand from November 18 at 8:00 AM GT through November 19. Additionally, Tarsus will host virtual one-on-one meetings on November 19. Interested parties can schedule a meeting through their Jefferies representative. For further details, including potential changes to the presentation schedule, visit www.tarsusrx.com. Tarsus is advancing its pipeline in eye care and other therapeutic areas.
Tarsus Pharmaceuticals reported significant progress in its pipeline and financial results for Q3 2021. The company is on track to complete enrollment in the Saturn-2 Phase 3 trial for TP-03 by year-end, with topline data expected in Q1 2022. They presented new data highlighting a large unmet need in Demodex blepharitis. Financially, Tarsus posted a net loss of $15.7 million this quarter, up from $10.1 million a year prior, with increased R&D and administrative expenses totaling $10.2 million and $6.7 million respectively. Cash reserves are at $184 million, supporting operations into mid-2023.
Tarsus Pharmaceuticals (NASDAQ: TARS) presented data on Demodex blepharitis at the AAOpt 2021 Annual Meeting, revealing it accounts for 69% of blepharitis cases. The study found existing treatments like tea tree oil are ineffective, highlighting a need for better solutions. The Atlas study noted significant psychosocial burdens faced by 80% of patients, with many suffering for over four years without diagnosis. Tarsus's investigational drug, TP-03, is currently in Phase 3 trials and aims to address this unmet medical need.